DK3570940T3 - Pridopidin til anvendelse i behandling af fragilt x-syndrom - Google Patents

Pridopidin til anvendelse i behandling af fragilt x-syndrom Download PDF

Info

Publication number
DK3570940T3
DK3570940T3 DK18741607.8T DK18741607T DK3570940T3 DK 3570940 T3 DK3570940 T3 DK 3570940T3 DK 18741607 T DK18741607 T DK 18741607T DK 3570940 T3 DK3570940 T3 DK 3570940T3
Authority
DK
Denmark
Prior art keywords
pridopidine
fragile
syndrome
treatment
Prior art date
Application number
DK18741607.8T
Other languages
Danish (da)
English (en)
Inventor
Michael Hayden
Mahmoud Abdulhossein Pouladi
Original Assignee
Prilenia Neurotherapeutics Ltd
Nat Univ Singapore
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd, Nat Univ Singapore, Agency Science Tech & Res filed Critical Prilenia Neurotherapeutics Ltd
Application granted granted Critical
Publication of DK3570940T3 publication Critical patent/DK3570940T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DK18741607.8T 2017-01-20 2018-01-18 Pridopidin til anvendelse i behandling af fragilt x-syndrom DK3570940T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448595P 2017-01-20 2017-01-20
PCT/US2018/014169 WO2018136600A1 (en) 2017-01-20 2018-01-18 Use of pridopidine for the treatment of fragile x syndrome

Publications (1)

Publication Number Publication Date
DK3570940T3 true DK3570940T3 (da) 2024-02-19

Family

ID=62908348

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18741607.8T DK3570940T3 (da) 2017-01-20 2018-01-18 Pridopidin til anvendelse i behandling af fragilt x-syndrom

Country Status (13)

Country Link
US (2) US11234973B2 (cg-RX-API-DMAC7.html)
EP (1) EP3570940B1 (cg-RX-API-DMAC7.html)
JP (1) JP7114604B2 (cg-RX-API-DMAC7.html)
CN (1) CN110505902B (cg-RX-API-DMAC7.html)
AU (1) AU2018210145B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019015000A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050700C (cg-RX-API-DMAC7.html)
DK (1) DK3570940T3 (cg-RX-API-DMAC7.html)
ES (1) ES2972205T3 (cg-RX-API-DMAC7.html)
HU (1) HUE068300T2 (cg-RX-API-DMAC7.html)
IL (1) IL268125B2 (cg-RX-API-DMAC7.html)
PL (1) PL3570940T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018136600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EP3503890B1 (en) 2016-08-24 2024-12-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating dystonias
MX390627B (es) 2016-08-24 2025-03-21 Prilenia Neurotherapeutics Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN111343982A (zh) 2017-09-08 2020-06-26 普瑞尼亚神经治疗有限公司 用于治疗药物诱发的异动症的普利多匹定
BR112021015346A2 (pt) 2019-02-04 2021-10-05 Prilenia Neurotherapeutics Ltd. Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo
JP7490064B2 (ja) * 2020-01-08 2024-05-24 ニューロヴェンティ カンパニー リミテッド リスリード化合物を有効成分として含む脆弱x症候群または関連発達障害治療用組成物
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
WO2008127188A1 (en) 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
JP2013532233A (ja) 2010-07-02 2013-08-15 アクティエボラゲット・エスコーエッフ 機械構成要素、および表面硬化方法
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
PL2667715T3 (pl) * 2011-01-27 2018-02-28 Neuren Pharmaceuticals Limited Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
CN104768545A (zh) * 2012-09-27 2015-07-08 泰华制药工业有限公司 雷沙吉兰和普多比啶组合以治疗神经退化性病症,尤其亨廷顿氏病
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
JP6949487B2 (ja) 2014-01-22 2021-10-13 プリレニア・ニューロセラピューティクス・エルティーディーPrilenia Neurotherapeutics Ltd プリドピジンの調節放出製剤
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease

Also Published As

Publication number Publication date
JP7114604B2 (ja) 2022-08-08
CN110505902B (zh) 2022-11-11
IL268125B2 (en) 2023-04-01
EP3570940A4 (en) 2020-10-28
PL3570940T3 (pl) 2024-06-17
EP3570940B1 (en) 2023-12-13
IL268125B (en) 2022-12-01
HUE068300T2 (hu) 2024-12-28
US20220202798A1 (en) 2022-06-30
WO2018136600A1 (en) 2018-07-26
US20190336488A1 (en) 2019-11-07
BR112019015000A2 (pt) 2020-04-07
CA3050700A1 (en) 2018-07-26
EP3570940A1 (en) 2019-11-27
AU2018210145B2 (en) 2023-06-29
AU2018210145A1 (en) 2019-08-29
JP2020514313A (ja) 2020-05-21
IL268125A (en) 2019-09-26
CN110505902A (zh) 2019-11-26
CA3050700C (en) 2023-10-03
US11234973B2 (en) 2022-02-01
ES2972205T3 (es) 2024-06-11

Similar Documents

Publication Publication Date Title
DK3570940T3 (da) Pridopidin til anvendelse i behandling af fragilt x-syndrom
EP3446667A4 (en) Absorbent article
DK3227675T3 (da) Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
EP3437612A4 (en) VOIDABLE ARTICLE
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
EP3446666A4 (en) VOIDABLE ARTICLE
EP3449883A4 (en) VOIDABLE ARTICLE
EP3545925A4 (en) ABSORBENT ARTICLE
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
EP3470034A4 (en) VOIDABLE ARTICLE
EP3446668A4 (en) VOIDABLE ARTICLE
EP3505148A4 (en) VOIDABLE ARTICLE
EP3384887A4 (en) VOIDABLE ARTICLE
EP3520752A4 (en) ABSORBENT ARTICLE
EP3470036A4 (en) VOIDABLE ARTICLE
EP3437608A4 (en) VOIDABLE ARTICLE
EP3354245A4 (en) VOIDABLE ARTICLE
EP3357469A4 (en) VOIDABLE ARTICLE
EP3437607A4 (en) VOIDABLE ARTICLE
HUE058314T2 (hu) Pridopidin alkalmazása Rett-szindróma kezelésére
EP3434240A4 (en) SUCTIONABLE ARTICLE
EP3549563A4 (en) ABSORBENT ARTICLE
EP3417840A4 (en) Absorbent article
EP3384888A4 (en) VOIDABLE ARTICLE
EP3492054A4 (en) VOIDABLE ARTICLE